PLANO, Texas--(BUSINESS WIRE)--
Adding extensive clinical, HEOR, and editorial expertise
STATinMED Research, a leading health economics and outcomes research (HEOR) company, announces Dr. Nora Janjan’s appointment as Chief Medical Officer. Dr. Janjan, formerly Professor at MD Anderson Cancer Center, will play a key role in STATinMED’s expansion within oncology and cardiology and will contribute her real-world clinical and HEOR expertise to research projects in all medical disciplines. Dr. Janjan has authored more than 180 peer-reviewed articles, 61 book chapters, and has served on numerous editorial boards. She has had extensive experience in shaping regulatory and health policy, serving on the Medicare Coverage Advisory Committee, National Cancer Institute Central Institutional Review Board, and Institute for Clinical and Economic Research (ICER), while also participating in developing standards of healthcare and quality assurance guidelines with AMA’s Physician’s Consortium for Performance Improvement, National Comprehensive Cancer Network (NCCN), National Quality Forum, American Society of Clinical Oncology (ASCO), American Society of Radiation Oncology, and the Joint Commission on Accreditation of Healthcare Organizations (JCAHO).
Joining recently appointed Dr. Doug Brenner, PhD, MBA, President, the addition of Dr. Janjan augments the scope of research and analytical capabilities of STATinMED Research. Dr. Brenner states, “While our uniquely comprehensive access to multiple data sources, proven analytical expertise and proprietary algorithms are already well-known throughout the industry, Dr. Janjan will enhance value in all STATinMED’s service offerings through her clinical, academic, public policy and HEOR expertise. Already working on the cutting edge of analytics, Dr. Janjan’s guidance adds an exciting new level of depth and versatility to our data team.”
Dr. Janjan’s medical academic experience includes tenured Professor in Radiation Oncology, and Symptom Research at MD Anderson Cancer Center where she served as Vice Chair of the Institutional Review Board, and Director of Health Care Policy in Radiation Oncology. She has held leadership positions in the American Society for Radiation Oncology (ASTRO) as past President, and the American Society of Clinical Oncology’s (ASCO) Conquer Cancer Foundation Board of Directors, and the Radiological Society of North America (RSNA).
About STATinMED Research
Founded in 2007, STATinMED Research is one of the world’s leading health economic and outcomes research companies using real-world data to generate evidence that provides the pharmaceutical and health care industries with insight for drug development and patient access. Through customized research methodologies and a diverse set of data sources, STATinMED’s team of professionals develop strategies that deliver better clinical outcomes, higher cost savings and greater value at every stage of the pharmaceutical product life cycle. The company collaborates with its clients to deliver demonstrable results that allow for greater confidence in marketability, cost effectiveness, product development and economic vitality. STATinMED is headquartered in Plano, Texas, with offices in Ann Arbor, Mich., and New York. For more information, visit their website at STATinMED.com and follow them on LinkedIn and Twitter.
The health economics and outcomes research industry has developed in recent years to answer questions about safety, effectiveness, expenditures and quality of life that are critical to effective disease management, health care administration, and public policy. HEOR is driven primarily by the observational, retrospective analysis of real-world evidence, using advanced algorithms to leverage large datasets—i.e., “Big Data.” This approach allows investigation of important questions that would not be feasible or ethical with traditional prospective research, such as randomized controlled clinical trials. Often with HEOR, the two approaches are used in tandem, with observational studies used to test pivotal controlled trial results against real-world outcomes. This new body of knowledge has facilitated decision making among clinicians and public policy stakeholders.